Physician profile
Nancy Dorman
NPI 1750801940
$2,405.16
in general payments reported to CMS, 2019-2025
19 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $646 · 2023: $741 · 2024: $214 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,186.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.41 | 2021-2025 | |
| Glaxosmithkline, LLC. | $447.08 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $222.54 | 2021-2023 | Ozempic, Rybelsus, Saxenda |
| Astrazeneca Pharmaceuticals LP | $181.97 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $138.99 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Astellas Pharma US INC | $105.95 | 2021-2023 | Veozah, Myrbetriq |
| Lilly USA, LLC | $102.70 | 2021-2025 | Jardiance, Emgality, Zepbound |
| Exact Sciences Corporation | $85.09 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $78.76 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.94 | 2023 | Stiolto Respimat, Spiriva Respimat |
| Sanofi-Aventis U.S. LLC | $36.57 | 2021-2022 | |
| Dexcom, INC. | $32.02 | 2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.94 | 2024 | Caplyta |
| Corium, LLC | $22.76 | 2024 | Azstarys |
| Alkermes, INC. | $21.45 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.02 | 2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $18.48 | 2022 | |
| Mylan Specialty L.P. | $17.68 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Dorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.